scispace - formally typeset
S

Silvio Garattini

Researcher at Mario Negri Institute for Pharmacological Research

Publications -  822
Citations -  22752

Silvio Garattini is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Fenfluramine & Serotonin. The author has an hindex of 70, co-authored 796 publications receiving 21819 citations.

Papers
More filters
Journal ArticleDOI

How to increase value and reduce waste when research priorities are set

TL;DR: This report discusses how avoidable waste can be considered when research priorities are set and recommends ways to improve the yield from basic research, and the transparency of processes by which funders prioritise important uncertainties should be increased.
Journal ArticleDOI

Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus

TL;DR: The induction of spontaneously recurring seizures in rats involves the activation of inflammatory cytokines and related pro‐ and anti‐inflammatory genes in the hippocampus and these changes may play an active role in hyperexcitability of the epileptic tissue.
Journal Article

Why rare diseases are an important medical and social issue. Commentary

TL;DR: The European Rare Disease Task Force of the Health and Consumers Protection Directorate General of the European Commission has set up a working group to collaborate with WHO on ICD-10, and is considering all other existing classifi cations to provide the rare-diseases community with a uniform system as mentioned in this paper.
Journal ArticleDOI

Clinical pharmacokinetics of diazepam.

TL;DR: Based on kinetic data, a single administration of diazepam at night should be adequate for hypnotic and anxiolytic effects in most patients and measurement of blood levels is unnecessary.
Journal ArticleDOI

Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy

TL;DR: The natural history of idiopathic membranous nephropathy is studied in patients who received only symptomatic therapy, and 24 of the 37 patients followed for at least five years had complete or partial remission of proteinuria.